Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 5, 2016, Pages 5461-5469

  Yang, Shuqun ^a   Luo, Chonglin ^a   Gu, Qingyang ^a   Xu, Qiang ^a   Wang, Guan ^a   Sun, Hongye ^a   Qian, Ziliang ^b   Tan, Yexiong ^c   Qin, Yuxin ^a   Shen, Yuhong ^a   Xu, Xiaowei ^d   Chen, Shu Hui ^a   Chan, Chi Chung ^a   Wang, Hongyang ^c   Mao, Mao ^a   Fang, Douglas D ^a,e  

^a WUXI APPTEC   (China)

^b JOHNSON AND JOHNSON   (United States)

^c Eastern Hepatobiliary Surgery Hospital   (China)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e China Novartis Institutes for Biomedical Research Co Ltd   (China)

Author keywords

HCC; JAK1; PDX; Ruxolitinib

Indexed keywords

JANUS KINASE 1; RUXOLITINIB; STAT3 PROTEIN; JAK1 PROTEIN, HUMAN; MESSENGER RNA; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENETIC PROCEDURES; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; JANUS KINASE 1 GENE; JANUS KINASE SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION SIGNALING PATHWAY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHARMACODYNAMICS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; WHOLE EXOME SEQUENCING; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; DRUG SCREENING; GENETICS; LIVER NEOPLASMS; MUTATION; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; FEMALE; HUMANS; JANUS KINASE 1; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; PHOSPHORYLATION; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958092771     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6684     Document Type: Article

References (34)

1. Venook AP, Papandreou C, Furuse J and de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. The oncologist. 2010; 15 Suppl 4:5-13.
2. El-Serag HB and Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340:745-750.
3. El-Serag HB, Davila JA, Petersen NJ and McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003; 139:817-823.
4. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology. 2010; 78 Suppl 1:7-10.
5. Bosetti C, Turati F and La Vecchia C. Hepatocellular carcinoma epidemiology. Best practice & research Clinical gastroenterology. 2014; 28:753-770.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378-390.
7. Vainchenker W and Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013; 32:2601-2613.
8. Yu H and Jove R. The STATs of cancer-new molecular targets come of age. Nature reviews Cancer. 2004; 4:97-105.
9. Furqan M, Mukhi N, Lee B and Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker research. 2013; 1:5.
10. Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, Yoo NJ and Lee SH. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:3716-3721.
11. Staerk J, Kallin A, Demoulin JB, Vainchenker W and Constantinescu SN. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem. 2005; 280:41893-41899.
12. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J, Hauptschein R, Rejto PA, Fernandez J, Wang G, Zhang Q, Wang B, et al. Wholegenome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome research. 2013; 23:1422-1433.
13. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7:387-397.
14. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR and Cancer Genome P. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365:1054-1061.
15. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M and Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352:1779-1790.
16. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T and Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366:787-798.
17. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Jr., Arcasoy MO, Hexner E, Lyons RM, et al. A double-blind, placebocontrolled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366:799-807.
18. Mascarenhas J and Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:3008-3014.
19. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115:3109-3117.
20. Shen Y, Devgan G, Darnell JE, Jr. and Bromberg JF. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci U S A. 2001; 98:1543-1548.
21. Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y and Liu D. STAT inhibitors for cancer therapy. Journal of hematology & oncology. 2013; 6:90.
22. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE. Stat3 as an Oncogene. Cell. 1999; 98:295-303.
23. Muntane J, De la Rosa AJ, Docobo F, Garcia-Carbonero R and Padillo FJ. Targeting tyrosine kinase receptors in hepatocellular carcinoma. Curr Cancer Drug Targets. 2013; 13:300-312.
24. Sethi G, Chatterjee S, Rajendran P, Li F, Shanmugam MK, Wong KF, Kumar AP, Senapati P, Behera AK, Hui KM, Basha J, Natesh N, Luk JM and Kundu TK. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Molecular cancer. 2014; 13:66.
25. Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF and Shiau CW. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Carcinogenesis. 2014; 35:2807-2814.
26. Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF and Shiau CW. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Neoplasia. 2014; 16:595-605.
27. Wilson GS, Tian A, Hebbard L, Duan W, George J, Li X and Qiao L. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer letters. 2013; 341:224-230.
28. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA and Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9:338-350.
29. Eirini Bournazou JB. Targeting the tumor microenvironment. JAKSTAT. 2013; 2:e23828.
30. Fang DD, Zhang B, Gu Q, Lira M, Xu Q, Sun H, Qian M, Sheng W, Ozeck M, Wang Z, Zhang C, Chen X, Chen KX, Li J, Chen SH, Christensen J, et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2014; 9:285-294.
31. Fang DD, Gao YB, Xu Q, Sun HY, Zhang B, Chen ZL, et al. Identification of somatic mutations in esophageal squamous cell carcinoma and corresponding xenograft by next-generation sequencing [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Abstract nr 2351.
32. Xu Q, Wang G, Fang DD, Gao YB, Chen YD, Sun LL, et al. Deep sequencing of Xenografts and case-matched blood and primary tumors reveals a 20 folds enrichment of loss of heterozygosity versus somatic mutations suggesting LOH plays an ever important role in tumorigenesis [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Abstract nr LB-397.
33. Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab RB, Wong A, John-Baptiste A, Bagrodia S, et al. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a Mutation. PLoS One. 2013; 8:e67258.
34. Evrot E, Ebel N, Romanet V, Roelli C, Andraos R, Qian Z, Dolemeyer A, Dammassa E, Sterker D, Cozens R, Hofmann F, Murakami M, Baffert F and Radimerski T. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:6230-6241.